MeSH Browser

MeSH Heading: Zalcitabine
Tree Number(s): D03.383.742.680.245.500.950; D13.570.230.329.950; D13.570.230.500.925; D13.570.685.245.500.950
Unique ID: D016047
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D016047
Scope Note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Entry Term(s): 2',3'-Dideoxycytidine; Dideoxycytidine; HIVID Roche; Hivid; NSC-606170; ddC (Antiviral)
Pharm Action: Antimetabolites
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Related Numbers: 7481-89-2
CAS Type 1 Name: Cytidine, 2',3'-dideoxy-
Previous Indexing: Deoxycytidine/analogs & derivatives (1986-1989); Dideoxynucleosides (1989)
Public MeSH Note: 94; was DIDEOXYCYTIDINE 1990-93
Online Note: use ZALCITABINE to search DIDEOXYCYTIDINE 1990-93
History Note: 94; was DIDEOXYCYTIDINE 1990-93
Date Established: 1990/01/01
Date of Entry: 1989/07/14
Revision Date: 2017/05/24

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0024532
Related Numbers: 7481-89-2
Scope Note: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Terms: Zalcitabine Preferred Term
Term UI T047678
Date01/01/1999
LexicalTag NON
ThesaurusID; 2',3'-Dideoxycytidine
Term UI T047674
Date07/03/1989
LexicalTag NON
ThesaurusID NLM (1990); ddC (Antiviral)
Term UI T047675
Date06/19/1989
LexicalTag NON
ThesaurusID NLM (1990); Dideoxycytidine
Term UI T047676
Date11/30/1992
LexicalTag NON
ThesaurusID NLM (1994)

Zalcitabine MeSH Descriptor Data 2025